Press Release
Press Release - Q2FY27
- Overall revenue grew 33% YoY to INR 4,178 Mn; EBITDA more than doubled to INR 769 Mn (+118% YoY)
- Base business revenue up 37% YoY to INR 3,273 Mn; EBITDA margin expanded 440 bps YoY to 23.6%
- Ibuprofen business revenue up 21% YoY; EBITDA loss narrowed to INR 2 Mn from INR 87 Mn
- PAT swung to INR 285 Mn profit from INR 101 Mn loss YoY
- Net debt reduced 19% to INR 5,000 Mn; net debt to EBITDA improved to 1.8x from 3.2x at FY26 end
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 SOLARA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add SOLARA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Solara Active Pharma Sciences Limited
Important.
The summary above is generated automatically from Solara Active Pharma Sciences Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.